As development continues on orismilast, which UNION therapeutics A/S believes will prove superior to Amgen, Inc.'s psoriasis drug Otezla, the Danish company has inked a potentially lucrative licensing deal with China's Innovent Biologics, Inc. for the next-generation PDE4 inhibitor.
Union Inks China Deal For Promising Skin Drug Orismilast
A Potential Rival To Amgen's Otezla
Innovent is paying the Danish biotech $20m upfront for the China rights to the mid-stage PDE4 inhibitor that is being developed for psoriasis, atopic dermatitis and hidradenitis suppurativa.
